AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 11 min read$ANIP

CAREY STEPHEN P. sold $207K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $72.80 ($0.21M total) on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Sep 1, 2026, 10:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ANIP
Bearish
medium confidence
Mentioned
$ANIP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPBearishLow
01

Why it matters

The CFO's sale reduces his ownership and may be interpreted as a negative signal, though the amount is modest.

02

Market read

Primary insider sale filing; modest impact but worth noting for short‑term traders.

03

What to watch

Potential tax planning or portfolio rebalancing could be driving the transaction rather than company outlook.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑08‑31

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ANIPBearishMedium confidence
Context

CFO Stephen Carey sold 2,850 shares for $207,480 via a 10b5‑1 plan, reducing his stake to 171,843 shares.

Expected impact

Modest downward pressure; price may dip 1‑2% in the next trading session.

Evidence & confidence

The sale amount is modest ($207k) but involves the CFO, suggesting a possible negative signal to the market.

Market effects

Sector

Minimal; the sale does not affect the broader pharmaceutical sector.

Regional

Limited to U.S. investors tracking ANI Pharmaceuticals.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged 10b5‑1 plan and not indicative of insider sentiment.

Key entities

  • Company
    ANI Pharmaceuticals Inc

    U.S. pharmaceutical company (ticker ANIP).

  • Executive
    Stephen P. Carey

    Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

SEP 4
$ANIPLow

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

finance.yahoo.com1 min
AUG 19
$ANIPMedAI 8/10

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.

aol.com6 min
AUG 14
$ANIPMedAI 8/10

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals reported Q2 2026 total net revenues of $266.0 million, up 25.9% year over year, and adjusted non-GAAP EBITDA of $71.6 million, up 32.4%. Cortrophin Gel revenues were $117.1 million (+43.5%). 2026 guidance: net revenue $1.08B-$1.14B, Cortrophin Gel $520M-$540M, adjusted EBITDA $285M-$300M, EPS $9.19-$9.69.

fool.com7 min